title: Hairy cell leukemia-variant treated with 2-chlorodeoxyadenosine--a report of three cases.
abstract: Three patients with B-prolymphocytic variant of HCL (HCL-V) were treated with a chlorinated purine analogue, 2-chlorodeoxyadenosine, at a daily dosage of 0.12 mg/kg in 2-hour intravenous infusion for 5 consecutive days. Partial remission was achieved in only 1 patient, who relapsed after 6 months. Two other patients did not respond to the treatment. HCL-V is a distinct clinicopathological entity which seems to be resistant to various therapeutic modalities. However, further observations are necessary in order to establish the efficacy of 2-CdA in the treatment of HCL-V.
authors.affiliation: Department of Hematology, Medical University of Lódz, Poland.
authors.forename: M
authors.initials: M
authors.lastname: Blasińska-Morawiec
authors.forename: T
authors.initials: T
authors.lastname: Robak
authors.forename: E
authors.initials: E
authors.lastname: Krykowski
authors.forename: A
authors.initials: A
authors.lastname: Hellmann
authors.forename: H
authors.initials: H
authors.lastname: Urbańska-Ryś
mesh_terms: D000368:Aged; D000954:Antigens, Surface / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007943:Leukemia, Hairy Cell / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D012074:Remission Induction; D013154:Spleen / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000954:Antigens, Surface; D000970:Antineoplastic Agents; D017338:Cladribine